IBA and NorthStar Medical Radioisotopes Sign Contract for Rhodotron® Electron Beam Accelerator for Commercial Production of Therapeutic Radioisotope Actinium-225 (Ac-225)
18 November 2021 - 2:00PM
IBA and NorthStar Medical Radioisotopes Sign Contract for
Rhodotron® Electron Beam Accelerator for Commercial Production of
Therapeutic Radioisotope Actinium-225 (Ac-225)
Louvain-La-Neuve, Belgium, and BELOIT,
Wis., USA November 18, 2021 – IBA (Ion
Beam Applications S.A., EURONEXT), the world leader in particle
accelerator technology, and NorthStar Medical Radioisotopes, LLC,
(‘NorthStar’) a global innovator in the development, production and
commercialization of radiopharmaceuticals used for therapeutic
applications and medical imaging, today announced a new contract in
which NorthStar will purchase a third Rhodotron® TT300 HE electron
beam accelerator from IBA.
The accelerator will be exclusively used for the
production of no-carrier added (n.c.a.) actinium-225 (Ac-225), an
important therapeutic radioisotope that is in highly limited supply
and for which no commercial-scale production technology currently
exists. NorthStar previously purchased two Rhodotron® accelerators
from IBA for its newly completed molybdenum-99 (Mo-99) production
facility.
“We look forward to continuing to work with IBA,
who have shown extensive commercial expertise and excellent
performance in delivering electron beam accelerators for our Mo-99
production expansion project,” said Stephen Merrick,
President and Chief Executive Officer of NorthStar.
“NorthStar is at the forefront of U.S. radioisotope production as
the only commercialized producer of the diagnostic imaging
radioisotope molybdenum-99 (Mo-99). We are applying that same
development expertise to rapidly advance large-scale availability
of the therapeutic radioisotope Ac-225 for use in oncology and
other indications, and we are excited about its potential in these
disease areas.”
Olivier Legrain, Chief Executive Officer
of IBA commented, “We are delighted to sign this latest
contract with NorthStar Medical Radioisotopes and to continue to
deliver innovative solutions for reliable radioisotope supply.
IBA’s Rhodotron® accelerators provide the most advanced electron
accelerator technology in the world, and we are excited for the
opportunity to create new therapeutic radioisotopes such as Ac-225.
With its radiotheranostic capabilities, combining targeted
diagnosis and therapy, we believe that this radioisotope has
significant potential in the treatment of cancer.”
The final stage of facility design is underway
for NorthStar’s state-of-the-art Therapeutic Radioisotope
production facility, which will be exclusively dedicated to Ac-225
production, with construction scheduled to begin in early 2022.
Initial production of Ac-225 is planned for late 2023, and a Drug
Master File will be submitted to the FDA in 2024. NorthStar’s
proprietary process for the production of Ac-225 will use IBA’s
Rhodotron® to enable commercial-scale n.c.a. Ac-225 production that
is free of long-life radioactive byproducts associated with other
production methods.
About Actinium-225 (Ac-225) and
Therapeutic Radiopharmaceuticals Ac-225 is a high energy
alpha-emitting radioisotope of significant interest by the medical
community for extensive use in clinical studies of targeted
radiopharmaceutical therapy (RPT). RPT combines select molecules
with therapeutic radioisotopes, such as Ac-225, to directly target
and deliver therapeutic doses of radiation to destroy cancer cells
in patients with serious disease. Ac-225 carries sufficient
radiation to cause cell death in a localized area of targeted
cells, while minimizing undesired dose to adjacent cells in
patients. Clinical research and commercial use of Ac-225 are
severely constrained by chronic short supply due to limitations of
current production technology. NorthStar’s electron accelerator
technology will produce high purity, no-carrier added (n.c.a.)
Ac-225, free of long-lived radioactive byproducts. NorthStar is
positioned to be the first commercial-scale producer of therapeutic
radioisotopes Ac-225 and copper-67 (Cu-67), applying its production
technology expertise to provide reliable supply for advancing
clinical research and supplying commercial radiopharmaceutical
products.
About IBAIBA (Ion Beam
Applications S.A.) is the world leader in particle accelerator
technology. The company is the leading supplier of equipment and
services in the field of proton therapy, considered to be the most
advanced form of radiation therapy available today. IBA is also a
leading player in the fields of industrial sterilization,
radiopharmaceuticals and dosimetry. The company, based in
Louvain-la-Neuve, Belgium, employs approximately 1,500 people
worldwide. IBA is a certified B Corporation (B Corp) meeting the
highest standards of verified social and environmental
performance.
IBA is listed on the pan-European stock exchange
EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).
More information can be found at:
www.iba-worldwide.com.
About NorthStar Medical Radioisotopes,
LLC (NorthStar)NorthStar Medical Radioisotopes is a
commercial-stage nuclear medicine company that manufactures and
distributes diagnostic and therapeutic radiopharmaceuticals. The
Company’s proprietary state-of-the art technology and proven
management team have propelled it to the forefront of U.S. medical
radioisotope production as the sole domestic producer of the
diagnostic imaging radioisotope molybdenum-99 (Mo-99). Mo-99 is
used to generate technetium-99m (Tc-99m), the standard of care in
diagnostic imaging to assess the extent and severity of heart
disease and cancer. NorthStar’s unique Mo-99 production process is
non-uranium based and environmentally friendly. NorthStar is
expanding its industry-leading position in the emerging area of
therapeutic radioisotopes, which are used in targeted
radiopharmaceutical therapy to treat cancer, respiratory and other
diseases. Using first-in-kind and environmentally-sound electron
accelerator technology, NorthStar is poised to be the first
commercial-scale producer of therapeutic radioisotopes actinium-225
(Ac-225) and copper-67 (Cu-67). For more information about
NorthStar’s comprehensive radiopharmaceutical portfolio, visit:
www.northstarnm.com.
CONTACTS:
For IBASoumya ChandramouliChief
Financial Officer+32 10 475 890Investorrelations@iba-group.com
Olivier LechienCorporate Communication
Director+32 10 475 890communication@iba-group.com
Consilium Strategic CommunicationsAmber Fennell,
Angela Gray, Lucy Featherstone+44 (0) 20 3709
5700IBA@consilium-comms.com
For NorthStar Medical Radioisotopes,
LLC Corporate:Lisa HolstVice President Sales and
Marketing678-471-9027
lholst@northstarnm.com
Investor Relations:Paul EstremExecutive Vice
President and Chief Financial
Officer608-987-8318pestrem@northstarnm.com
Media:Priscilla
Harlan781-799-7917pharlan@shiningrockllc.com
- 211118-NorthStar_IBA_Ac225_accelerator_contract_final-EN
Ion Beam Applications (EU:IBAB)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Ion Beam Applications (EU:IBAB)
Historical Stock Chart
Von Apr 2023 bis Apr 2024